Sandoz Group AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SDZNY research report →
About the company
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.
- CEO
- Richard Saynor
- IPO
- 2023
- Employees
- 22,678
- HQ
- Basel, IDF, CH
Price Chart
- Market Cap
- $38.82B
- P/E
- 42.29
- P/S
- 3.49
- P/B
- 4.13
- EV/EBITDA
- 23.22
- Div Yield
- 1.11%
- Gross Margin
- 47.19%
- Op Margin
- 14.60%
- Net Margin
- 8.22%
- ROE
- 10.09%
- ROIC
- 7.81%
- Revenue
- $11.15B · 7.36%
- Net Income
- $919.12M · 91812.09%
- EPS
- $2.13 · 0.00%
- Op Income
- $1.71B
- FCF YoY
- 1250.00%
- 52W High
- $94.15
- 52W Low
- $54.51
- 50D MA
- $83.85
- 200D MA
- $76.06
- Beta
- 0.50
- Avg Volume
- 28.35K
Get TickerSpark's AI analysis on SDZNY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SDZNY coverage
Recent articles, reports, and earnings notes.
No research on SDZNY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SDZNY report →Similar companies
Peers in the same neighborhood.